Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5914)
All Articles published online
|
Publishing Process of This Article
|
Dec 10, 2015 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Fazio N. Neuroendocrine tumors resistant to mammalian target of rapamycin inhibitors: A difficult conversion from biology to the clinic. World J Clin Oncol 2015; 6(6): 194-197 [PMID: 26677429 DOI: 10.5306/wjco.v6.i6.194] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v6/i6/194.htm |
| Number | Citing Articles |
| 1 |
Ramon Salazar, Rocio Garcia-Carbonero, Steven K. Libutti, Andrew E. Hendifar, Ana Custodio, Rosine Guimbaud, Catherine Lombard-Bohas, Sergio Ricci, Heinz-Josef Klümpen, Jaume Capdevila, Nicholas Reed, Annemiek Walenkamp, Enrique Grande, Sufiya Safina, Tim Meyer, Oliver Kong, Herve Salomon, Ranjana Tavorath, James C. Yao. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors. The Oncologist 2018; 23(7): 766 doi: 10.1634/theoncologist.2017-0144
|
| 2 |
Viviana Vergaro, Monica Civallero, Cinzia Citti, Maria Cosenza, Francesca Baldassarre, Giuseppe Cannazza, Samantha Pozzi, Stefano Sacchi, Francesco Fanizzi, Giuseppe Ciccarella. Cell-Penetrating CaCO3 Nanocrystals for Improved Transport of NVP-BEZ235 across Membrane Barrier in T-Cell Lymphoma. Cancers 2018; 10(2): 31 doi: 10.3390/cancers10020031
|
| 3 |
Claus von Hessert-Vaudoncourt, Sara Lelek, Christina Geisler, Teresa Hartung, Vanessa Bröker, Franziska Briest, Liliana Mochmann, Fabian Jost-Brinkmann, Dagmar Sedding, Joana Benecke, Helma Freitag, Sebastian Wolfshöfer, Hedwig Lammert, Svenja Nölting, Michael Hummel, Jörg Schrader, Patricia Grabowski. Concomitant inhibition of PI3K/mTOR signaling pathways boosts antiproliferative effects of lanreotide in bronchopulmonary neuroendocrine tumor cells. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1308686
|
| 4 |
Teresa Gagliano, Claudio Brancolini. Targeting histone deacetylases for combination therapies in neuroendocrine tumors. Cancer Gene Therapy 2021; 28(6): 547 doi: 10.1038/s41417-020-00260-x
|
| 5 |
Simona Falletta, Stefano Partelli, Corrado Rubini, Dominik Nann, Andrea Doria, Ilaria Marinoni, Vanessa Polenta, Carmelina Di Pasquale, Ettore degli Uberti, Aurel Perren, Massimo Falconi, Maria Chiara Zatelli. mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors. Endocrine-Related Cancer 2016; 23(11): 883 doi: 10.1530/ERC-16-0329
|
| 6 |
Julien Bollard, Céline Patte, Patrick Massoma, Isabelle Goddard, Nicolas Gadot, Noura Benslama, Valérie Hervieu, Carole Ferraro-Peyret, Martine Cordier-Bussat, Jean-Yves Scoazec, Colette Roche, Thomas Walter, Cécile Vercherat. Combinatorial Treatment with mTOR Inhibitors and Streptozotocin Leads to Synergistic In Vitro and In Vivo Antitumor Effects in Insulinoma Cells. Molecular Cancer Therapeutics 2018; 17(1): 60 doi: 10.1158/1535-7163.MCT-17-0325
|
| 7 |
Diana Martins, Francesca Spada, Ioana Lambrescu, Manila Rubino, Chiara Cella, Bianca Gibelli, Chiara Grana, Dario Ribero, Emilio Bertani, Davide Ravizza, Guido Bonomo, Luigi Funicelli, Eleonora Pisa, Dario Zerini, Nicola Fazio. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors. Targeted Oncology 2017; 12(5): 611 doi: 10.1007/s11523-017-0506-5
|
| 8 |
Svenja Nölting, Jakob Rentsch, Helma Freitag, Katharina Detjen, Franziska Briest, Markus Möbs, Victoria Weissmann, Britta Siegmund, Christoph J. Auernhammer, Elke Tatjana Aristizabal Prada, Michael Lauseker, Ashley Grossman, Samantha Exner, Christian Fischer, Carsten Grötzinger, Jörg Schrader, Patricia Grabowski, Aamir Ahmad. The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models. PLOS ONE 2017; 12(8): e0182852 doi: 10.1371/journal.pone.0182852
|
| 9 |
Biagio Cangiano, Letizia Maria Fatti, Luca Persani, Giovanni Vitale. Nuovi farmaci a bersaglio molecolare nei tumori neuroendocrini gastroenteropancreatici. L'Endocrinologo 2017; 18(6): 280 doi: 10.1007/s40619-017-0359-2
|
| 10 |
Bhavina D.O. Batukbhai, Ana De Jesus-Acosta. The Molecular and Clinical Landscape of Pancreatic Neuroendocrine Tumors. Pancreas 2019; 48(1): 9 doi: 10.1097/MPA.0000000000001189
|
| 11 |
Sara Zanini, Serena Renzi, Francesco Giovinazzo, Giovanna Bermano. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs). Frontiers in Endocrinology 2020; 11 doi: 10.3389/fendo.2020.562505
|
| 12 |
E T Aristizabal Prada, C J Auernhammer. Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets. Endocrine Connections 2018; 7(1): R1 doi: 10.1530/EC-17-0286
|